Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update

Sensus Healthcare, Inc. (NASDAQ:SRTS - Get Free Report) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,210,000 shares, an increase of 107.4% from the December 15th total of 583,500 shares. Based on an average trading volume of 203,100 shares, the days-to-cover ratio is currently 6.0 days. Currently, 9.2% of the company's shares are short sold.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently modified their holdings of the company. Truvestments Capital LLC bought a new stake in shares of Sensus Healthcare in the 3rd quarter valued at $32,000. XTX Topco Ltd acquired a new position in shares of Sensus Healthcare during the second quarter valued at about $95,000. Cubist Systematic Strategies LLC purchased a new stake in Sensus Healthcare in the 2nd quarter valued at $156,000. Acadian Asset Management LLC boosted its stake in shares of Sensus Healthcare by 578.6% in the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company's stock worth $239,000 after buying an additional 38,474 shares during the last quarter. Finally, Marshall Wace LLP increased its holdings in Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company's stock worth $412,000 after buying an additional 46,732 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company's stock.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded up $0.26 during mid-day trading on Tuesday, reaching $6.64. The company had a trading volume of 260,744 shares, compared to its average volume of 236,868. Sensus Healthcare has a one year low of $2.61 and a one year high of $9.33. The firm has a market cap of $108.82 million, a price-to-earnings ratio of 11.65 and a beta of 1.21. The business's 50-day simple moving average is $7.68 and its 200 day simple moving average is $6.70.

Analysts Set New Price Targets

Several analysts recently commented on SRTS shares. Maxim Group raised their price objective on Sensus Healthcare from $12.00 to $14.00 and gave the stock a "buy" rating in a research note on Friday, November 15th. HC Wainwright upped their target price on shares of Sensus Healthcare from $10.00 to $11.00 and gave the stock a "buy" rating in a research note on Monday, November 18th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.